DeepMed Research

Seagen Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 1998-01-01

Employees: 3.2K

Market Cap: -

Website: http://www.seagen.com

Clinical Trials

A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Esophageal Squamous Cell Carcinoma
Gastroesophageal Junction Adenocarcinoma
Squamous Cell Carcinoma of Head and Neck
Esophageal Adenocarcinoma
Gastric Adenocarcinoma
Carcinoma, Non-Small Cell Lung

Interventions: Drug: sigvotatug vedotin

First Posted Date: 2024-08-12

Last Posted Date: 2025-05-14

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 6

Registration Number: NCT06549816

Locations: 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳
Union Hospital Affiliated to Tongji Medical College,Huazhong University of science and Technology, Wuhan City, Hubei, China

A Study of SGN-MesoC2 in Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung
Ovarian Neoplasms
Pancreatic Adenocarcinoma
Colorectal Neoplasms
Mesothelioma
Other Solid Tumors
Endometrial

Interventions: Drug: PF-08052666

First Posted Date: 2024-06-20

Last Posted Date: 2025-05-22

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 365

Registration Number: NCT06466187

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
The University of Kansas Clinical Research Center, Fairway, Kansas, United States
🇺🇸
The University of Kansas Hospital Cambridge North Tower A, Kansas City, Kansas, United States

and more 15 locations

Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors

First Posted Date: 2024-04-12

Last Posted Date: 2024-04-12

Lead Sponsor: Seagen Inc.

Registration Number: NCT06362590

A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers

Phase 1

Recruiting

Conditions: Lymphoma, T-Cell, Peripheral
Lymphoma, Large B-Cell, Diffuse
Hodgkin Disease
Lymphoma, Large-Cell, Anaplastic

Interventions: Drug: PF-08046044/SGN-35C

First Posted Date: 2024-02-12

Last Posted Date: 2025-05-15

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 210

Registration Number: NCT06254495

Locations: 🇺🇸
The University of Kansas Hospital Cambridge Tower A, Kansas City, Kansas, United States
🇺🇸
The University of Kansas Hospital, Kansas City, Kansas, United States
🇺🇸
The University of Kansas Medical Center Medical Office Building, Kansas City, Kansas, United States

and more 39 locations

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Phase 2

Recruiting

Conditions: Breast Neoplasms
Gastroesophageal Junction Adenocarcinoma
HER2 Low Breast Neoplasms
HER2 Positive Breast Neoplasms
Stomach Neoplasms
Triple Negative Breast Neoplasms
Metastatic Breast Cancer
Metastatic Gastric Cancer
Advanced Breast Cancer
Advanced Gastric Cancer

Interventions: Drug: disitamab vedotin
Drug: tucatinib

First Posted Date: 2023-12-06

Last Posted Date: 2025-05-13

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 172

Registration Number: NCT06157892

Locations: 🇪🇸
Ecg Medica Sl, Valencia, Spain
🇺🇸
Arizona Cancer Center / University of Arizona, Tucson, Arizona, United States
🇺🇸
Banner-University Medical Center Tucson Campus, Tucson, Arizona, United States

and more 115 locations

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung
Stomach Neoplasms
Small Cell Lung Carcinoma
Gastroesophageal Junction Adenocarcinoma
Colorectal Neoplasms
Pancreatic Ductal Adenocarcinoma

Interventions: Drug: PF-08046050
Drug: bevacizumab

First Posted Date: 2023-11-14

Last Posted Date: 2025-05-13

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 494

Registration Number: NCT06131840

Locations: 🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸
Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida, United States
🇺🇸
SCRI Oncology Partners, Nashville, Tennessee, United States

and more 35 locations

A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers

Phase 1

Recruiting

Conditions: Lymphoma, Large-Cell, Anaplastic
Lymphoma, Non-Hodgkin
Lymphoma, T-Cell, Peripheral
Lymphoma, T-Cell, Cutaneous
Hodgkin Disease
Lymphoma, Large B-Cell, Diffuse

Interventions: Drug: PF-08046045

First Posted Date: 2023-11-07

Last Posted Date: 2025-05-21

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 150

Registration Number: NCT06120504

Locations: 🇺🇸
University of Arkansas For Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
University of Miami Hospital and Clinics - Lennar, Coral Gables, Florida, United States
🇺🇸
University of Miami Hospital And Clinics, Miami, Florida, United States

and more 33 locations

A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Phase 3

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: sigvotatug vedotin
Drug: docetaxel

First Posted Date: 2023-08-25

Last Posted Date: 2025-05-13

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 670

Registration Number: NCT06012435

Locations: 🇨🇭
Inselspital, Bern, Other, Switzerland
🇫🇷
Hospital Center De Cornouaille, Quimper Cedex, Other, France
🇫🇷
Centre Hospitalier Universitaire de Rennes, Hopital Pontchaillou, Rennes, Other, France

and more 258 locations

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Phase 2

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung
Ovarian Neoplasms
Endometrial Neoplasms
Head and Neck Neoplasms

Interventions: Drug: disitamab vedotin

First Posted Date: 2023-08-21

Last Posted Date: 2025-05-13

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 119

Registration Number: NCT06003231

Locations: 🇺🇸
Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola, New York, United States
🇩🇪
Charite Campus Benjamin Franklin, Berlin, Germany
🇩🇪
Charite Berlin-Campus Virchow, Berlin, Germany

and more 109 locations

A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung
Pancreatic Ductal Adenocarcinoma
Colorectal Neoplasms
Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: SGN-EGFRd2
Drug: PF-08046052

First Posted Date: 2023-08-09

Last Posted Date: 2025-05-13

Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Target Recruit Count: 290

Registration Number: NCT05983133

Locations: 🇺🇸
UCLA Department of Medicine - Hematology & Oncology, Santa Monica, California, United States
🇺🇸
Moffitt Cancer Center McKinley Hospital, Tampa, Florida, United States
🇺🇸
University of Iowa, Iowa City, Iowa, United States

and more 10 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy